Cancer treatment targeting dll3
AssigneeAmgen Inc.
InventorsNooshin Hashemi Sadraei, Mukul Minocha, Amanda Goldrick, Xi Chen, Mira Kistler
Life of this patent
Estimating the term…
Abstract
Invention disclosed herein provides a method for the treatment of DLL3-positive cancer or SCLC, comprising administering to a subject in need thereof an anti-DLL3 agent alone, or in combination with an anti-PD-L 1 antibody and/or chemotherapeutic agents. Step dosing or extended IV infusion of the anti-DLL3 agent is also disclosed.
Claims59
A method of treating DLL3-positive cancer, comprising administering to a subject in need thereof an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs:
- 13 and 23, wherein the anti-DLL3 agent is administered at a dose of from 10 mg to 100 mg twice every three weeks.
A method of treating DLL3-positive cancer, comprising administering to a subject in need thereof an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs:
- 13 and 23, wherein the anti-DLL3 agent is administered at a dose of from 20 mg to 200 mg once every three weeks.
A method of treating DLL3-positive cancer comprising administering to a subject in need thereof an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs:
- 13 and 23, wherein the anti-DLL3 agent is administered according to the following regimen:
- a) administering the anti-DLL3 agent in a first cycle wherein (i) the anti-DLL3 agent is administered at a dose of from 1 mg to 200 mg by continuous intravenous infusion over a period of 2 days to 7 days, and (ii) after the continuous intravenous infusion, the anti-DLL3 agent is administered by a bolus intravenous infusion on day 8, day 15, or both day 8 and day 15, and
- b) administering the anti-DLL3 agent according to any one of i) to iii) below:
- i) administering one or more subsequent doses of the anti-DLL3 agent at a dose of from 10 mg to 100 mg starting on day 29 and once every two weeks thereafter;
- ii) administering one or more subsequent doses of the anti-DLL3 agent at a dose of from 10 mg to 100 mg starting on day 22 and twice every three weeks thereafter;
- and
- iii) administering one or more subsequent doses of the anti-DLL3 agent at a dose of from 20 mg to 200 mg starting on day 22 and thereafter once every three weeks.
A method of treating DLL3-positive cancer, comprising administering to a subject in need thereof an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs:
- 13 and 23, an anti-PD-L1 antibody, and optionally one or more chemotherapeutic agents, wherein the anti-DLL3 agent is administered according to any one of a) to c) below:
- a) administering the anti-DLL3 agent at a dose of from 10 mg to 100 mg once every two weeks;
- b) administering the anti-DLL3 agent at a dose of from 10 mg to 100 mg twice every three weeks;
- and
- c) administering the anti-DLL3 agent at a dose of from 20 mg to 200 mg once every three weeks.
A method of treating DLL3-positive cancer, comprising administering to a subject in need thereof an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs:
- 13 and 23, and an alkylating agent, wherein the anti-DLL3 agent is administered to the subject at a dose of from 10 mg to 200 mg once every three weeks.
A method of treating DLL3-positive cancer, comprising administering to a subject in need thereof an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs:
- 13 and 23, and an alkylating agent, wherein the anti-DLL3 agent is administered to the subject according to the following:
- a first dose of 0 mg or 1 mg on day 1, a second dose of from 10 mg to 100 mg on day 8, a third dose of from 10 mg to 200 mg on day 15, and one or more subsequent doses of from 10 mg to 200 mg starting on day 22 and once every three weeks thereafter.
Dependencies are inferred from the claim text.